Şerife Mehtap Kanbur

Şerife Mehtap Kanbur

Auto-generated profile, based on publicly available information

Şerife Mehtap Kanbur

Department of Pediatric Hematology Oncology & Bone Marrow Transplantation Unit Ankara Bilkent City Hospital Ankara Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2024 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
BABegüm Avcı
Begüm Avcı
ÖBÖzlem Arman Arman Bilir
Özlem Arman Arman Bilir
SÖSare Gülfem Özlü
Sare Gülfem Özlü
ŞKŞerife Mehtap Kanbur
Şerife Mehtap Kanbur
DGDilek Gürlek Gökçebay
Dilek Gürlek Gökçebay
NÖNamık Yaşar Özbek
Namık Yaşar Özbek

12 April 2022 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Open access
PDF file
ÖBÖzlem Arman Arman Bilir
Özlem Arman Arman Bilir
MIMelek Işık
Melek Işık
MKMehtap Kanbur
Mehtap Kanbur
IBIkbal Ok Bozkaya
Ikbal Ok Bozkaya
NÖNamık Yaşar Özbek
Namık Yaşar Özbek
During CD34 + stem cell count to determine the number of stem cells in the allografts from pediatric donors, we noticed a considerable amount of early hematogones (eHGs) within the stem cell gate in flow cytometry. Since the number of hematogones causes a decrease in the total number of stem cells counted within the graft, we planned a retrospective study to analyze the effect of eHGs on transplant outcomes. We also wanted to show how allografts containing high amounts of early HGs affect transplant outcomes. Quantification of CD34 numbers and the number of eHGs were determined by flow cytometry. Patients were divided into 2 groups according to the number of CD 34+ cells calculated after subtracting the number of hematogones within the allograft. Those who received < 2 × 106/kg CD34+ cells and ≥ 2 × 106/kg were defined as group 1 and 2, respectively. Twenty-six patients and their 26 donors were included in the study. The median age of patients was 6.5 years and 5.4 years in Group 1 and 2, respectively. The median donor age was 9 years in Group 1 and 7 years in Group 2. The ages and genders were similar in the two groups (p > 0.05). The number of nucleated cells given to both groups was not different. The number of early hematogones given to both groups was similar (p = 0.93). The mean times to myeloid and platelet engraftments were also similar in the two groups. In this study, we provided trilineage engraftment to all patients in two groups. We could not find a considerable effect of these eHGs in myeloid and platelet engraftments. However, the number of patients included in our study is low, therefore we suggest a study including a large number of donors in order to confirm our findings.

9 January 2025 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
ÖBÖzlem Arman Arman Bilir
Özlem Arman Arman Bilir
BKBetül Karaatmaca
Betül Karaatmaca
IBIkbal Ok Bozkaya
Ikbal Ok Bozkaya
ŞKŞerife Mehtap Kanbur
Şerife Mehtap Kanbur
DKDilek Kaçar
Dilek Kaçar
NÖNamık Yaşar Özbek
Namık Yaşar Özbek